- Home
- KFS vs LXEO Comparison
KFS vs LXEO Comparison
Compare KFS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KFS | LXEO |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.7M | 418.9M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KFS | LXEO |
|---|---|---|
| Price | $10.45 | $5.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 80.4K | ★ 843.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,996,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.42 | N/A |
| 52 Week Low | $7.28 | $1.45 |
| 52 Week High | $16.80 | $10.99 |
Technical Indicators
Market Signals| Indicator | KFS | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 41.17 |
| Support Level | N/A | $4.93 |
| Resistance Level | $14.83 | $6.08 |
| Average True Range (ATR) | 0.42 | 0.43 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 43.20 | 38.83 |
Price Performance
Historical ComparisonAbout KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.